Search our website

Press Releases

VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 3rd, 2021
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
April 28th, 2021
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
April 27th, 2021
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research
April 26th, 2021
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21st, 2021
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
April 12th, 2021
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
March 15th, 2021
CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants
March 10th, 2021
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
March 9th, 2021
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021
March 2nd, 2021
VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference
March 1st, 2021
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
February 2nd, 2021
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
January 21st, 2021
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
January 15th, 2021
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
December 23rd, 2020
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
December 7th, 2020
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
December 2nd, 2020
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
December 1st, 2020
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
November 23rd, 2020
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
November 19th, 2020

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top